China General Manager
Weidong Dai has served as Anpac Bio’s China General Manager since April 2015.
Our world class leaders started with a question, “What if we could detect cancer before tumors start?”
Our patented Cancer Differentiation Analysis (CDA) technology reinvents cancer screening and early detection with a “Blood Biopsy” that has no side effects in patients.
*As of September 30, 2019
Read about our CDA technology at the Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.Read the full article